78706-26-0

Basic information

• Product Name: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE;5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(WXG02934)
• CAS NO: 78706-26-0
• Molecular Formula: C₅H₂Cl₂N₄
• Molecular Weight: 189
• Product Categories: Heterocycles, Miscellaneous Reagents
• Mol File: 78706-26-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(78706-26-0)
• EPA Substance Registry System: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(78706-26-0)

Safety Data

• Hazardous Substances Data: 78706-26-0(Hazardous Substances Data)

Usage

Uses

5,7-Dichloro-[1,2,4]triazolo[1,5-a]pyrimidine is used in the synthesis of triazolopyrimidine inhibitors displaying antimalarial activity.

Upstream product

• 61-82-5 3-amino-1,2,4-triazole 
• 105-53-3 diethyl malonate 
• 40775-75-5 [1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol 

Relevant articles and documents

BCL6-targeting aromatic ring five-membered aromatic heterocyclic micromolecular organic compound and derivative and application thereof

The invention discloses an aromatic ring five-membered aromatic heterocyclic micromolecular organic compound or related analogues or pharmaceutically acceptable salts thereof. The structures of the compound are shown as formulas (I-IX). The invention also

The identification of GPR3 inverse agonist AF64394; The first small molecule inhibitor of GPR3 receptor function

The identification of the novel and selective GPR3 inverse agonist AF64394, the first small molecule inhibitor of GPR3 receptor function, is described. Structure activity relationships and syntheses based around AF64394 are reported.

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.